LUCIUS 卢修斯 普纳替尼 Ponatinib白血病

普纳替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Ponatinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Each tablet contains Ponatimib HCL 48.08mg equivalent

LUCIUS

白血病

LuciPona is a kimase inhibitor indicated for the

PHARMACEUTICALS

kasie shaco ic Dichronie mveloid leakemia (CML)

*Chronic phese ICPie
with resistance or intolerance to at least two prior kinase
Acccicrated pEEse (AP) or blast phase (BP) CML

LuciPona

paase, or blast pliaselor T3TL
ASEols Of Cse: LueiPone is Bot indieated and is not

Ponatinib Tablets

Tecorimended for the treatment of eafier tswith nawly

45mg

FDA批准

eted Dosage in CP.CMIL: Stertine dose is
Itg orally once datle wh a rec
uaty uponacaievemeat of S1eRCR.ARL
Recommended Dosags in AP-CML, BP-CMIL, 20g

*Hepatic Impairm
oru eedethe starting dose to 50

Rx Only

ona may be taken with or withocttocuk
medicine out of th
Warnins:
ereacitoa in Pregnancy and
pafient treatment
PLEASE SEE PACKAGE INSERI
Manufactured aad Marketed by

权威认证

LUCIUS

Tlongmang village. Xaythany district
Vientiane Canital, Laos
www.lucins la
Warning : To be sold by retail on poaso
Dy Tedr on prescraplion
boeysicians oniy, and as direste

30 Tablets

口碑质量

适应症:
普纳替尼是一种激酶抑制剂,适用于治疗患有以下疾病的成年患者:
1、慢性期(CP)慢性粒细胞白血病(CML),对至少两种先前的激酶抑制剂具有耐
药性或不耐受性。
2、加速期(AP)或母细胞期(BP)CML或费城染色体阳性急性淋巴细胞白血病

(Ph+ALL),没有其他激酶抑制剂。
3、T3151阳性CML(慢性期、加速期或爆发期)或T3151阴性Ph+ALL。
推荐剂量:
1、CP-CML的推荐剂量:起始剂量为45 mg,每日口服一次;当BCR-
ABL1IS≤1%时,减至15mg,每日一次。
2、AP-CML、BP-CML和Ph+ALL的推荐剂量:起始剂量为45mg,每日口服一次。
3、肝损伤患者:将起始剂量降至30mg,每日口服一次。

4、随餐服用或不随餐服用均可。